Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures
Registry of Myriad™ Utilization in Soft Tissue Reconstruction Procedures
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.
This is an observational, multi-center, single arm, Phase IV study, designed to evaluate the safety and clinical outcomes of Matrix and Morcells in soft tissue reconstruction procedures.
The study is a registry study and will enroll participants who are undergoing a surgical procedure, and where the attending physician will use Myriad Matrix™ and/or Morcells™ as part of the surgical intervention.
Participants enrolled in the study will be undergoing a range of surgical procedures involving the reconstruction of soft tissues, including but not limited to:
Other procedure types may be included at the discretion of the Investigator/Research Team.
Participants that are being enrolled in the study would otherwise be undergoing their surgical procedure with either of the Myriad™ devices as part of Standard of Care (SoC).
The pre-operative care and preparation of the surgical site (prior to the application of Myriad™ devices) shall be undertaken at the discretion of the attending physician and per their institutional protocols and procedures. Surgical technique for the participants reconstruction is at the discretion of the attending physician. Use of Myriad Matrix™ or Morcells as part of the surgery shall be per the products Instructions for Use. Myriad Matrix™ devices may be implanted or used for dermal regeneration as part of the participants surgical procedure. Myriad Morcells™ may be used for dermal regeneration and in combination with the Myriad Matrix™ devices. The participants post-operative care is at the discretion of the attending physician.
Early and late-stage healing outcomes will be assessed as part of the study and as part of standard of care.
Through the course of treatment and following up care de-identified patient data (quantitative qualitative assessment measures and digital images) will be captured and from the basis of the registry dataset.
Inclusion Criteria:
Exclusion Criteria:
barnaby.may@aroa.com+64 21 056 9995
Brandon.Bosque@aroa.com
Phoenix, Arizona 85008, United States
Poughkeepsie, New York 12601, United States
Greensboro, North Carolina 27401-1004, United States
Columbus, Ohio 43210, United States
Kymberly.palmer@ascension.org813-843-1398
Emily.murdoch@nghs.com(770)-219-3438
asmi60@lsuhsc.edu504-903-9009
flau@lsuhsc.edu504-412-1240
443-220-1438
Medoza.ameen@pennmedicine.upenn.edu223-221-1177
tcarver@mcw.edu414-955-1751
414-955-1751